Akari Therapeutics Partners with Whitehawk on Preclinical ADC Research
Event summary
- Akari Therapeutics and Whitehawk Therapeutics have entered a strategic research collaboration to evaluate the combination of Akari's PH1 spliceosome-modulating payload with Whitehawk’s topoisomerase I inhibitor (TOP1i) ADC platform.
- The collaboration will involve multiple preclinical workstreams designed to assess dual payload compatibility and synergies, with interim data updates expected as studies progress.
- Akari will lead the design, execution, and evaluation of the research activities, while both companies will jointly review resulting data for potential broader development discussions.
The big picture
This collaboration underscores a strategic shift toward dual-payload ADCs, an emerging trend aimed at enhancing the efficacy of cancer treatments. By combining their proprietary technologies, Akari and Whitehawk are positioning themselves to potentially lead in next-generation oncology therapeutics. The success of this partnership could influence broader industry adoption of spliceosome-modulating payloads in ADC development.
What we're watching
- Technical Validation
- Whether the preclinical studies will validate the compatibility and synergies of Akari's PH1 payload with Whitehawk’s TOP1i ADC platform.
- Development Pipeline
- The pace at which the collaboration could lead to broader development opportunities between the two companies.
- Market Differentiation
- How the potential first-in-class dual payload technology will position Akari and Whitehawk in the competitive ADC landscape.
Related topics